Cost of atopic dermatitis and eczema in the United States.
about
House dust mite reduction and avoidance measures for treating eczemaOral evening primrose oil and borage oil for eczemaHouse dust mite reduction and avoidance measures for treating eczemaProbiotics for treating eczemaTopical pimecrolimus for eczemaOral evening primrose oil and borage oil for atopic eczemaParents' reported preference scores for childhood atopic dermatitis disease statesNanoparticle-Enabled Transdermal Drug Delivery Systems for Enhanced Dose Control and Tissue TargetingOverview of Reviews The prevention of eczema in infants and children: an overview of Cochrane and non-Cochrane reviews.Genetic and environmental risk factors for childhood eczema development and allergic sensitization in the CCAAPS cohortEczema prevalence in the United States: data from the 2003 National Survey of Children's HealthText messages as a reminder aid and educational tool in adults and adolescents with atopic dermatitis: a pilot studyIL-13Rα2 has a protective role in a mouse model of cutaneous inflammationLong-term safety of tacrolimus ointment in children treated for atopic dermatitis.Therapeutic potential of macrolide immunosuppressants in dermatology.Probiotics for prevention of atopic diseases in infants: systematic review and meta-analysis.The contribution of health services research to improved dermatologic care.Atopic Dermatitis: A Cross-Sectional (Descriptive) Study of 100 CasesSkin care in the well term newborn: two systematic reviews.Fat-soluble vitamins and atopic disease: what is the evidence?Mental health comorbidity in patients with atopic dermatitis.Does cost-effectiveness play a role in clinical trials?Safety of topical calcineurin inhibitors for the treatment of atopic dermatitis.Topical calcineurin inhibitors and lymphoma risk: evidence update with implications for daily practice.The socioeconomic impact of atopic dermatitis in the United States: a systematic review.Development and initial validation of a Traditional Chinese Medicine symptom-specific outcome measure: a Zheng-related atopic dermatitis symptom questionnaire (ZRADSQ).Burden of skin diseases.Transcutaneous yellow fever vaccination of subjects with or without atopic dermatitis.Atopic dermatitis burden scale: creation of a specific burden questionnaire for families.Cost of care of atopic dermatitis in IndiaFactors contributing to poor treatment outcomes in childhood atopic dermatitis.Long-term effect of early-life supplementation with probiotics on preventing atopic dermatitis: A meta-analysis.Burden of Atopic Dermatitis in the United States: Analysis of Healthcare Claims Data in the Commercial, Medicare, and Medi-Cal Databases.Immunologic Targets in Atopic Dermatitis and Emerging Therapies: An Update.Does breastfeeding protect against the development of eczema?Improving allergy management in the primary care network--a holistic approach.Early weaning is beneficial to prevent atopic dermatitis occurrence in young children.Impact of a Pediatric Dermatology Service on Emergency Department Utilization for Children with Dermatitis.Overexpression of AQP3 and AQP10 in the skin exacerbates psoriasiform acanthosisThe role of airborne proteins in atopic dermatitis.
P2860
Q24186585-2D48AA3E-4F08-430E-8AC9-22C82F1B372EQ24197709-01B792FF-0995-4CEB-A080-451E162254FBQ24239879-2D7C67BC-6AD3-4D04-AE37-293757C6071AQ24241429-BA080491-111C-44F9-9E05-70DA21A352BAQ24243250-59B31096-F35B-42C7-82D7-6047BFBE7F31Q24250119-6F219C4E-358B-4EF0-B10E-450B7C1A8BE6Q24795485-2CCE6937-9790-495D-8919-B8A564238317Q28079462-EE8E54AC-FB0A-46F7-AC25-77A7EDB34810Q30521278-181B6E05-7C93-44D8-97DB-8E0F04733688Q33596206-30D17D74-A299-4F20-8EC3-4B40166145A1Q33672814-25AAF77D-5F82-476C-99D9-EAFDEFC8669BQ34159532-6556A066-7018-44B4-B0C7-A1B5D7BDC5F8Q34610797-B59F99D9-3C40-48B2-9605-AA0D33217E6DQ35208400-DC038FA6-6B93-41BD-A370-B019F0DF4D76Q35680649-60C01C8A-773C-4F8F-9F41-7F75A6B1A803Q35704386-B105DC77-F5AA-43F8-B82C-5188FD23D066Q35757300-71F1214E-5111-4A31-9E22-6DF1BE814089Q36147769-FA841EC1-BD8D-4EDB-A455-B4D8598A4D3BQ36243495-342F8F3F-22AA-4CB8-ABFE-D1C468475FE2Q36486394-D47AE151-2877-411B-90A0-B5776042B047Q36590438-8EDAF077-4FA3-49FE-A582-1F341B2BFF47Q36835056-EE1C9940-15C3-4158-AE48-C3B6A0BD5D09Q36861654-A6A03B5D-E486-48C4-AD0C-ED4CD97FD13DQ36892767-CA394B89-A2D2-44DE-A7A2-CD69245AE7ABQ37096167-9816F7C6-7AB1-4802-B13C-0EFD91AC11F4Q37434358-B7F109FC-4A05-4728-B0CA-A37776D38233Q37519631-00A24EE3-C181-4520-BF86-89539F6C5CC1Q37649830-4BBB4141-7622-4D0A-8CCA-589642E26F11Q38107026-011FA947-5544-43A7-9B2C-11BA9CBCD76CQ38391148-3C09FCD8-477C-4ACA-800D-BB5C123ADE14Q38394059-2D550F14-AC6A-40CA-BE60-7ED68EFF2887Q38459877-65F1E35B-B647-4AA5-AF44-187E6A9459FDQ38679654-7471FC79-A1A9-4BA4-BF47-A24E5F7410B9Q38883893-4A76288B-758B-4EFB-BCEB-3DAB73CCF723Q39159690-E7A40D99-7A84-4650-8853-EEF12B7182F9Q39334666-BB8D76B5-EFD3-4187-B93E-35008B4E3D9EQ39985482-87E9B6FD-4F6E-4BDB-898D-D7074BF7E177Q40323997-521B7074-20AF-48F0-8898-A09D2E4CD18DQ41641512-C0F48FD0-DC88-4801-AEE1-7984D840920EQ42217684-12B1904C-7C2C-4644-B702-722431EE03E1
P2860
Cost of atopic dermatitis and eczema in the United States.
description
2002 nî lūn-bûn
@nan
2002 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մարտին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Cost of atopic dermatitis and eczema in the United States.
@ast
Cost of atopic dermatitis and eczema in the United States.
@en
type
label
Cost of atopic dermatitis and eczema in the United States.
@ast
Cost of atopic dermatitis and eczema in the United States.
@en
prefLabel
Cost of atopic dermatitis and eczema in the United States.
@ast
Cost of atopic dermatitis and eczema in the United States.
@en
P2093
P356
P1476
Cost of atopic dermatitis and eczema in the United States.
@en
P2093
C Ralph Daniel
Charles N Ellis
Diane L Whitaker-Worth
J Wang Cheng
Kuo B Tong
Lynn A Drake
Mark Boguniewicz
Mark Lebwohl
Mary M Prendergast
Seth R Stevens
P304
P356
10.1067/MJD.2002.120528
P407
P577
2002-03-01T00:00:00Z